In this outcome measure, number of participants were classified according to their habit of taking daytime rest (naps) as never, always and sometimes. Never is defined as someone who does not take any daytime nap, always is defined as someone who takes daytime naps daily and sometimes is defined as someone who takes daytime naps on weekends or on holidays.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

In this outcome measure, number of participants were classified according to their habit of taking daytime rest (naps) as never, always and sometimes. Never is defined as someone who does not take any daytime nap, always is defined as someone who takes daytime naps daily and sometimes is defined as someone who takes daytime naps on weekends or on holidays.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

In this outcome measure, number of participants were classified according to their habit of taking daytime rest (naps) as never, always and sometimes. Never is defined as someone who does not take any daytime nap, always is defined as someone who takes daytime naps daily and sometimes is defined as someone who takes daytime naps on weekends or on holidays.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

In this outcome measure, number of participants were classified according to their habit of taking daytime rest (naps) as never, always and sometimes. Never is defined as someone who does not take any daytime nap, always is defined as someone who takes daytime naps daily and sometimes is defined as someone who takes daytime naps on weekends or on holidays.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

In this outcome measure, number of participants were classified according to the presence or absence of fatigue based on their habit of performing aerobic physical exercise as never, always and sometimes.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Here, "Number Analyzed" signifies number of participants evaluable for specified rows.

In this outcome measure, number of participants were classified according to the presence or absence of fatigue based on their habit of performing aerobic physical exercise as never, always and sometimes.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Here, "Number Analyzed" signifies number of participants evaluable for specified rows.

In this outcome measure, number of participants were classified according to the presence or absence of fatigue based on their habit of performing aerobic physical exercise as never, always and sometimes.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Here, "Number Analyzed" signifies number of participants evaluable for specified rows.

In this outcome measure, number of participants were classified according to the presence or absence of fatigue based on their habit of performing aerobic physical exercise as never, always and sometimes.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Here, "Number Analyzed" signifies number of participants evaluable for specified rows.

FACIT-F was a 13-item questionnaire which assessed self-reported fatigue and its impact upon daily activities and function. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0= not at all; 1= a little bit; 2= somewhat; 3= quite a bit; 4= very much). FACIT-F score was calculated by summing the 13 items (range 0 [not at all] to 52 [very much]); higher scores represented less fatigue and better status of participants.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

FACIT-F was a 13-item questionnaire which assessed self-reported fatigue and its impact upon daily activities and function. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0= not at all; 1= a little bit; 2= somewhat; 3= quite a bit; 4= very much). FACIT-F score was calculated by summing the 13 items (range 0 [not at all] to 52 [very much]); higher scores represented less fatigue and better status of participants.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

FACIT-F was a 13-item questionnaire which assessed self-reported fatigue and its impact upon daily activities and function. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0= not at all; 1= a little bit; 2= somewhat; 3= quite a bit; 4= very much). FACIT-F score was calculated by summing the 13 items (range 0 [not at all] to 52 [very much]); higher scores represented less fatigue and better status of participants.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

FACIT-F was a 13-item questionnaire which assessed self-reported fatigue and its impact upon daily activities and function. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0= not at all; 1= a little bit; 2= somewhat; 3= quite a bit; 4= very much). FACIT-F score was calculated by summing the 13 items (range 0 [not at all] to 52 [very much]); higher scores represented less fatigue and better status of participants.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

FACIT-F was a 13-item questionnaire which assessed self-reported fatigue and its impact upon daily activities and function. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0= not at all; 1= a little bit; 2= somewhat; 3= quite a bit; 4= very much). FACIT-F score was calculated by summing the 13 items (range 0 [not at all] to 52 [very much]); higher scores represented less fatigue and better status of participants.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

FACIT-F was a 13-item questionnaire which assessed self-reported fatigue and its impact upon daily activities and function. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0= not at all; 1= a little bit; 2= somewhat; 3= quite a bit; 4= very much). FACIT-F score was calculated by summing the 13 items (range 0 [not at all] to 52 [very much]); higher scores represented less fatigue and better status of participants.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

FACIT-F was a 13-item questionnaire which assessed self-reported fatigue and its impact upon daily activities and function. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0= not at all; 1= a little bit; 2= somewhat; 3= quite a bit; 4= very much). FACIT-F score was calculated by summing the 13 items (range 0 [not at all] to 52 [very much]); higher scores represented less fatigue and better status of participants.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

In this outcome measure, the number of participants were classified on the basis of the time of taking the oral medication - "morning, afternoon or night". Morning was anytime between 7 am to 12 pm. Afternoon was anytime between 1 pm and 7 pm. Night was anytime between 8 pm to 6 am. Participants who did not take medication were also classified.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

In this outcome measure, the number of participants were classified on the basis of the time of taking the oral medication - "morning, afternoon or night". Morning was anytime between 7 am to 12 pm. Afternoon was anytime between 1 pm and 7 pm. Night was anytime between 8 pm to 6 am. Participants who did not take medication were also classified.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

In this outcome measure, the number of participants were classified on the basis of the time of taking the oral medication - "morning, afternoon or night". Morning was anytime between 7 am to 12 pm. Afternoon was anytime between 1 pm and 7 pm. Night was anytime between 8 pm to 6 am. Participants who did not take medication were also classified.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

In this outcome measure, the number of participants were classified on the basis of the time of taking the oral medication - "morning, afternoon or night". Morning was anytime between 7 am to 12 pm. Afternoon was anytime between 1 pm and 7 pm. Night was anytime between 8 pm to 6 am. Participants who did not take medication were also classified.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

In this outcome measure, the number of participants were classified on the basis of the time of taking the oral medication - "morning, afternoon or night". Morning was anytime between 7 am to 12 pm. Afternoon was anytime between 1 pm and 7 pm. Night was anytime between 8 pm to 6 am. Participants who did not take medication were also classified.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

In this outcome measure, the number of participants were classified on the basis of the time of taking the oral medication - "morning, afternoon or night". Morning was anytime between 7 am to 12 pm. Afternoon was anytime between 1 pm and 7 pm. Night was anytime between 8 pm to 6 am. Participants who did not take medication were also classified.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

In this outcome measure, the number of participants were classified on the basis of the time of taking the oral medication - "morning, afternoon or night". Morning was anytime between 7 am to 12 pm. Afternoon was anytime between 1 pm and 7 pm. Night was anytime between 8 pm to 6 am. Participants who did not take medication were also classified.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

In this outcome measure, number of participants were classified according to the number of changes to dose that is (i.e). 0, 1 or 2 occurred per treatment cycle during 9 months of follow-up.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Here, "Number Analyzed" signifies number of participants evaluable for specified rows.

In this outcome measure, number of participants were classified according to the number of interruptions to dose i.e. 0, 1, 2, 3 or 4 occurred in each treatment cycle during 9 months follow-up.

Analysis population included all eligible participants who were included in this study. Here, "Number Analyzed" signifies number of participants evaluable for specified rows.

Best response was recorded from start of treatment with TKI until best complete response (CR), partial response (PR), stable disease (SD) or disease progression (DP) was achieved. RECIST v1.1, a) CR: disappearance of all lesions; any pathological lymph nodes (target lesions [TLs]) or non-target lesions (non-TLs) must have reduction in short axis to <10 mm; normalization of tumor marker level for non-TLs; b) PR: >=30% decrease in sum of diameter of all TLs, taking as reference baseline sum of diameters; c) DP: >=20% increase in sum of diameter of all TLs, taking as reference the smallest sum on study (including baseline measurement), sum must also be absolute increase of >=5 mm. Unequivocal progression of existing non TLs. Appearance of at least 1 new lesion; d) SD: neither sufficient shrinkage to qualify for PR nor sufficient increase in lesions to qualify for PD referring smallest sum diameter. Participant whose best response was not determined were classified as "Undetermined".

Analysis population included all eligible participants who were included in this study.

In this outcome measure, the mean duration of treatment was calculated and reported below.

Analysis population included all eligible participants who were included in this study.

TTF was defined as the time from the start of treatment with a TKI to tumour progression, treatment discontinuation for any reason or death from any cause. Participants who did not had the event were censored on the date of their final follow-up. Per RECIST 1.1, tumour progression: >=20% increase in sum of diameter of all measured target lesions, taking as reference smallest sum on study (including baseline measurement) of diameter of all target lesions, sum must also demonstrate an absolute increase of >=5 mm. Unequivocal progression of existing non target lesions. Appearance of at least 1 new lesion.

Analysis population included all eligible participants who were included in this study.

In this outcome measure, number of participants were classified according to number of treatment cycles received.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

PFS was defined as the time from the start of treatment with a TKI to tumour progression or death for any reason. Participants who, did not had the event were censored on the date of their final follow-up. Per RECIST v1.1, tumour progression: >=20% increase in sum of diameter of all measured target lesions, taking as reference smallest sum on study (including baseline measurement) of diameter of all target lesions, sum must also demonstrate an absolute increase of >=5 mm. Unequivocal progression of existing non target lesions. Appearance of at least 1 new lesion.

Analysis population included all eligible participants who were included in this study.

ORR was defined as the percentage of participants who achieved CR or PR. Per RECIST V1.1, a) CR: disappearance of all lesions; any pathological lymph nodes (target lesions or non-target lesions) must have reduction in short axis to <10 mm; normalization of tumor marker level for non-TLs; b) PR: >=30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters.

Analysis population included all eligible participants who were included in this study.

In participants who achieved CR or PR, DOR was defined as the duration from the documentation date of CR or PR to the first day when DP was observed. Per RECIST V1.1, a) CR: disappearance of all lesions; any pathological lymph nodes (target lesions or non-target lesions must have reduction in short axis to <10 mm; normalization of tumor marker level for non-target lesions; b) PR: >=30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters; c) DP: >=20% increase in sum of diameter of all measured target lesions, taking as reference smallest sum on study (including baseline measurement), sum must also demonstrate an absolute increase of >=5 mm. Unequivocal progression of existing non TLs. Appearance of at least 1 new lesion.

Analysis population included all eligible participants who were included in this study. Here 'Overall Number of Participants Analyzed' signifies participants with documented CR or PR.

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. In this outcome measure number of participants with fatigue event were classified into following: CTCAE grade 1 to 2 and CTCAE grade 3 to 4.

Analysis population included all eligible participants who were included in this study. Here, "Overall Number of Participants Analyzed" signifies participants with fatigue event.

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. In this outcome measure number of participants with hand foot syndrome event were classified into following: CTCAE grade 1 to 2 and CTCAE grade 3 to 4.

Analysis population included all eligible participants who were included in this study. Here, "Overall Number of Participants Analyzed" signifies participants with hand foot syndrome event.

AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. In this outcome measure number of participants with HFS event graded per CTCAE version 4.0 at Week 12 are reported.

Analysis population included all eligible participants who were included in this study. Here, 'Overall Number of Participants Analyzed' signifies participants with HFS event at Week 12.

AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. In this outcome measure number of participants with HFS event graded per CTCAE version 4.0 at Week 24 are reported.

Analysis population included all eligible participants who were included in this study. Here, 'Overall Number of Participants Analyzed' signifies participants with HFS event at Week 24.

AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. In this outcome measure number of participants with HFS event graded per CTCAE version 4.0 at Week 36 are reported.

Analysis population included all eligible participants who were included in this study. Here, 'Overall Number of Participants Analyzed' signifies participants with HFS event at Week 36.